VWM
BMRN icon

Vermillion Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vermillion Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$621 – 1655
2026
Q1 		$621 Buy
+11
New +$641 ﹤0.01% 949

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vermillion Wealth Management's BMRN Position: Q2 2026 in Review

Vermillion Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 11 shares — an estimated $621 sold.

Vermillion Wealth Management first reported a position in BMRN in Q1 2026 and held it in 1 quarter. The position peaked at $621 in Q1 2026. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Vermillion Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 11 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $621.
  • Vermillion Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's BioMarin Pharmaceuticals position peaked at $621 in Q1 2026.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.